{"id":"NCT00374322","sponsor":"GlaxoSmithKline","briefTitle":"Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer","officialTitle":"A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2011-09","completion":"2013-07","firstPosted":"2006-09-11","resultsPosted":"2014-08-18","lastUpdate":"2014-08-18"},"enrollment":3166,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Neoplasms, Breast"],"interventions":[{"type":"DRUG","name":"lapatinib","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Lapatinib","type":"EXPERIMENTAL"}],"summary":"This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant chemotherapy and have no clinical or radiographic evidence of disease.","primaryOutcome":{"measure":"Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])","timeFrame":"From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])","effectByArm":[{"arm":"Lapatinib 1500 mg","deltaMin":252,"sd":null},{"arm":"Placebo","deltaMin":290,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.286"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":26,"exclusionCount":17},"locations":{"siteCount":439,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Croatia","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Latvia","Lithuania","Mexico","New Zealand","Peru","Philippines","Poland","Russia","Slovakia","South Africa","South Korea","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["25752740","24687830","23234763"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":99,"n":1573},"commonTop":["Diarrhoea","Rash","Nausea","Fatigue","Headache"]}}